AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1672878
Drug: Levocabastine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levocabastine (0.5 mg/ml)
Trial: 1685691
Drug: Sodium cromoglycate
RxNorm normalized name: Sodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium cromoglycate (20 mg/ml)
Trial: 28078825
Drug: Ethanol 70%
RxNorm normalized name: Ethanol 70% Topical application Pad
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol 70% + unfractionated heparin 2000 U/mL
Trial: 14988279
Drug: Transdermal 17‐beta‐estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal 17‐beta‐estradiol
Trial: 9562227
Drug: Water (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water (250 ml)
Trial: 30606259
Drug: Combined criteria
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined criteria of total CTC count ≥10/5 mL and proportion of mesenchymal CTCs >10.7%
Trial: 29445928
Drug: Lapatinib and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib and trastuzumab (6 weeks) followed by lapatinib and trastuzumab plus weekly paclitaxel (12 weeks) with prolonged anti-HER2 therapy (18 weeks)
Trial: 29445928
Drug: Lapatinib and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib and trastuzumab (6 weeks) followed by lapatinib and trastuzumab plus weekly paclitaxel (12 weeks) with standard anti-HER2 therapy (6 weeks)
Trial: 29445928
Drug: Lapatinib and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib and trastuzumab (6 weeks) followed by lapatinib and trastuzumab plus weekly paclitaxel (12 weeks) with endocrine therapy
Trial: 29445928
Drug: Lapatinib and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib and trastuzumab (6 weeks) followed by lapatinib and trastuzumab plus weekly paclitaxel (12 weeks) without endocrine therapy
Trial: 29445928
Drug: Prolonged anti-HER2
RxNorm normalized name: anti-CD11a
DrugBank: Efalizumab (DB00095)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Prolonged anti-HER2 therapy
Trial: 27567886
Drug: Rotigotine ≤8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotigotine ≤8 mg/24 h for early PD (HY 1 and 2)
Trial: 26334249
Drug: Full-dose TIV
RxNorm normalized name: Rho(D) immune globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-dose TIV (0.5 mL)
Trial: 26334249
Drug: Half-dose TIV
RxNorm normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half-dose TIV (0.25 mL)
Trial: 20497416
Drug: tolterodine-ER +
RxNorm normalized name: tolterodine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tolterodine-ER + α-blocker
Trial: 12688447
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg of caffeine
Trial: 25147328
Drug: Atorvastatin 80
RxNorm normalized name: atorvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 80 mg/d (in subgroup with diabetes mellitus)
Trial: 22251025
Drug: Quality improvement
RxNorm normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quality improvement (QI) intervention designed to improve access to antidepressant medications and/or cognitive behavior therapy
Trial: 11738120
Drug: Vitamin D(3)
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D(3) infusions
Trial: 2471025
Drug: Inosine-pranobex (INPX)
RxNorm normalized name: inosine pranobex
DrugBank: Inosine pranobex (DB13156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inosine-pranobex (INPX) 1000 mg every 6 hours for 3 months
Trial: 169536
Drug: ACTH 4-10
RxNorm normalized name: ACTH
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ACTH 4-10 (30 mg/s.c.)
Trial: 31069442
Drug: Baseline 25OHD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline 25OHD ≥ 50 nmol/L
Trial: 24158313
Drug: Early removal
RxNorm normalized name: Super Spot Remover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early removal group (chest tube removal at drainage volume of 300 ml/24 h or less)
Trial: 24158313
Drug: Traditional management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional management group (chest tube removal when drainage volume is less than 100 ml/24 h)
Trial: 15959612
Drug: Cisapride (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride (30 mg/day)
Trial: 15959612
Drug: Bethanechol combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bethanechol combined with cisapride (30 mg/day each)
Trial: 12642049
Drug: Interferon alfa-2a
RxNorm normalized name: Interferon Alfa-2A
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alfa-2a (10 million units/m2, daily for 7 days)
Trial: 10757556
Drug: Amifostine (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amifostine (1000 mg absolute)
Trial: 3904977
Drug: Specific Immunotherapy
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific Immunotherapy Group - three monthly doses of 500 micrograms of tumor associated antigen (TAA) emulsified with complete Freund's adjuvant (CFA)
Trial: 3904977
Drug: Nonspecific Immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonspecific Immunotherapy Group - three monthly doses of CFA emulsified in saline
Trial: 3904977
Drug: Control Group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control Group - no treatment postoperatively
Trial: 28990437
Drug: Overall patient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall patient acceptance of injection pain
Trial: 20056354
Drug: Dose difference
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose difference map in bladder neck (trigonal region)
Trial: 11940375
Drug: DHEAS (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEAS (100 mg q.d.) for 6 months
Trial: 8571309
Drug: DIC treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DIC treatment
Trial: 2407959
Drug: Warfarin and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin and Aspirin (active treatment arms)
Trial: 27171136
Drug: Pentoxifylline (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (400 mg daily)
Trial: 25588369
Drug: Moro juice
RxNorm normalized name: tamarind juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moro juice extract (Morosil(®), 400 mg/die)
Trial: 22106341
Drug: GH replacement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH replacement therapy (0.24 mg/day in elderly, 0.33 mg/day in younger)
Trial: 9329355
Drug: GH replacement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH replacement therapy
Trial: 19843623
Drug: Atorvastatin (Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (Group I) for 15 days prior to surgery
Trial: 19843623
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Group II) with no antihyperlipidemic agents
Trial: 15271972
Drug: Two-implant ball
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-implant ball attachment group
Trial: 19807860
Drug: Well-being therapy
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Well-being therapy
Trial: 14602757
Drug: Immediate-release glipizide
RxNorm normalized name: glipizide Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release glipizide
Trial: 7882817
Drug: Glipizide-GITS (controlled-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glipizide-GITS (controlled-release glipizide)
Trial: 24961363
Drug: Contingency management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contingency management (CM) targeting psycho-stimulants
Trial: 21735527
Drug: Provisional stenting
RxNorm normalized name: Clearskin Professional Daily Correcting
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Provisional stenting with drug-eluting stents (DES) in group OR (stenosis < 50% of SB lumen area)
Trial: 1720370
Drug: Low-dose bleomycin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose bleomycin (60 units)
Trial: 2684006
Drug: Tetracycline (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetracycline (1 g)
Trial: 24917661
Drug: Multidose metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multidose metronidazole (500 mg twice daily for 7 days)
Trial: 30601374
Drug: Single-dose metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose metronidazole (2 g single-dose)
Trial: 23891275
Drug: Pioglitazone 30mg
RxNorm normalized name: GLIMEPIRIDE 2MG/PIOGLITAZONE 30MG TAB
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pioglitazone 30mg daily
Trial: 29256535
Drug: Gemfibrozil 600mg
RxNorm normalized name: GEMFIBROZIL 600MG TAB
DrugBank: Gemfibrozil (DB01241)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gemfibrozil 600mg daily
Trial: 26655100
Drug: Active balance
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active balance exercises (progressive, highly challenging group exercise program, twice weekly for 90 minutes)
Trial: 25234605
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (DE)
Trial: 4684623
Drug: Marijuana cigarette
RxNorm normalized name: Picea mariana resin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marijuana cigarette containing 4.8 mg Delta(9)-THC
Trial: 4684623
Drug: Marijuana cigarette
RxNorm normalized name: Picea mariana resin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marijuana cigarette containing 9.1 mg Delta(9)-THC
Trial: 7976985
Drug: Prophylactic aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prophylactic aspirin therapy
Trial: 7976985
Drug: Nicotine substitutes
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine substitutes as adjunctive therapy in smoking cessation
Trial: 7976985
Drug: Beta-blocker therapy
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blocker therapy following myocardial infarction
Trial: 7976985
Drug: Anti-inflammatory agents
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-inflammatory agents in the treatment of asthma
Trial: 7976985
Drug: Antidepressant drugs
RxNorm normalized name: MAO A Inhibitors, antidepressant drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant drugs as therapy for mild depression
Trial: 29068266
Drug: Weekly general
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly general support (Control)
Trial: 26631904
Drug: Red wine
RxNorm normalized name: Red wine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red wine extract of onion (RO) (250 mL for 10 weeks)
Trial: 26631904
Drug: Red wine
RxNorm normalized name: Red wine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red wine (RW) (250 mL for 10 weeks)
Trial: 25085534
Drug: Anticholinergic drugs
RxNorm normalized name: Anticholinergics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticholinergic drugs (most frequently in haloperidol group)
Trial: 17852312
Drug: Power-assisted functional
RxNorm normalized name: guaifenesin
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Power-assisted functional electrical stimulation (FES) therapy
Trial: 9267580
Drug: Orthodontic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orthodontic treatment without expansion
Trial: 3509066
Drug: 5-mg melatonin
RxNorm normalized name: melatonin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-mg melatonin
Trial: 22493073
Drug: Hydrochlorothiazide (HCTZ)
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HCTZ) 25 to 50 mg
Trial: 22493073
Drug: Amiloride (10-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiloride (10-20 mg)
Trial: 22493073
Drug: Nebivolol (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebivolol (5 to 10 mg)
Trial: 17463213
Drug: Intravenous midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous midazolam 2 mg + oral aprepitant 125 mg
Trial: 9378843
Drug: Intravenous midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous midazolam 2 mg
Trial: 11104314
Drug: Behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral treatment (Beh) group (unmedicated)
Trial: 9314913
Drug: Oral micronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral micronized E2 (2 mg daily)
Trial: 8393365
Drug: Cytosine arabinoside
RxNorm normalized name: Cytosine arabinoside
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cytosine arabinoside (ara-C) as a repair inhibitor of cyclophosphamide (Cy) resistance
Trial: 2873131
Drug: Alprazolam (3.67
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam (3.67 mg)
Trial: 2873131
Drug: Imipramine (167
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine (167 mg)
Trial: 18502262
Drug: Fenofibrate (FENO)
RxNorm normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fenofibrate (FENO) 160 mg/day
Trial: 28625503
Drug: Ezetimibe (EZE)
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ezetimibe (EZE) 10 mg/day
Trial: 17333838
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy using delta‐aminolevulinic acid in a water‐in‐oil emulsion applied to lesions, repeated once a week for a month
Trial: 12804082
Drug: Throat Coat
RxNorm normalized name: Menthol 2.5 mg ORAL PASTILLE [Throat Coat]
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Throat Coat (5-8 oz, 4-6 times daily)
Trial: 12804082
Drug: Placebo (5-8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (5-8 oz, 4-6 times daily)
Trial: 31839677
Drug: Docetaxel plus
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel plus MEK inhibitor selumetinib
Trial: 19556637
Drug: Lacto-G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lacto-G
Trial: 18555932
Drug: S(‐)‐amlodipine nicotinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S(‐)‐amlodipine nicotinate 2.5 mg QD
Trial: 18555932
Drug: Amlodipine besylate
RxNorm normalized name: Amlodipine Besylate
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine besylate 5 mg QD
Trial: 8067483
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral treatment
Trial: 11074998
Drug: Graftskin plus
RxNorm normalized name: GRAFTSKIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Graftskin plus compression therapy
Trial: 6791596
Drug: Nebulised sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulised sodium cromoglycate (20 mg four times daily)
Trial: 6791596
Drug: Oral choline
RxNorm normalized name: choline Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral choline theophyllinate (6.7 mg/kg four times daily)
Trial: 28215136
Drug: Systematic prevention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systematic prevention and treatment of fever
Trial: 21885077
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of albendazole (400mg)
Trial: 21885077
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of mebendazole (500mg)
Trial: 21885077
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of albendazole (400mg) and mebendazole (500mg)
Trial: 21885077
Drug: Double dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double dose of albendazole (400mg/400mg)
Trial: 21885077
Drug: Double dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double dose of mebendazole (500mg/500mg)
Trial: 21885077
Drug: Single drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single drugs (albendazole or mebendazole)
Trial: 21885077
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (albendazole + mebendazole)
Trial: 19703830
Drug: Inhaled salmeterol
RxNorm normalized name: salmeterol Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled salmeterol 50 microg + fluticasone propionate 500 microg twice daily
Trial: 19703830
Drug: Good adherence
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Good adherence (>80% use of study medication)
Trial: 17854028
Drug: MYP (myeloid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MYP (myeloid cell purging system) during treatment interruption
Trial: 14973305
Drug: Indinavir 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indinavir 800 mg q8h with rifabutin 300 mg qd
Trial: 3348966
Drug: PUVA treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PUVA treatment for 14 days
Trial: 31802233
Drug: Needle group
RxNorm normalized name: NEEDLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Needle group (20 ml of 0.5% ropivacaine via needle)
Trial: 20681818
Drug: Gel
RxNorm normalized name: Gel
DrugBank: Sepia esculenta bone (DB16562)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel
Trial: 26148007
Drug: Ad35.CS.01 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad35.CS.01 vaccine followed by two doses of RTS,S/AS01 (ARR-group)
Trial: 26148007
Drug: Three doses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses of RTS,S/AS01 (RRR-group)
Trial: 24019080
Drug: Adalimumab (ADA)
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adalimumab (ADA) at 160/80/40 mg every two weeks
Trial: 24019080
Drug: Azathioprine (AZA)
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azathioprine (AZA) at 2 mg/kg/day
Trial: 24019080
Drug: Mesalamine at
RxNorm normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mesalamine at 3 g/day
Trial: 9425965
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg bupivacaine
Trial: 10551572
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg ropivacaine
Trial: 10551572
Drug: 12 mg
RxNorm normalized name: pectin 12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg ropivacaine
Trial: 10551572
Drug: 14 mg
RxNorm normalized name: iodine 0.14 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14 mg ropivacaine
Trial: 6837621
Drug: Clonidine (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (0.3 mg daily)
Trial: 6837621
Drug: Prazosin (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin (15 mg daily)
Trial: 6837621
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of clonidine and prazosin
Trial: 27062079
Drug: Tapentadol prolonged
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tapentadol prolonged release (PR) 100-250 mg bid
Trial: 30660342
Drug: Trigger Point
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trigger Point Injection (TPI)
Trial: 28845548
Drug: Topical adhesive
RxNorm normalized name: menthol TOPICAL ADHESIVE PATCH, MEDICATED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical adhesive pads
Trial: 23739758
Drug: Osteopathic manual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osteopathic manual treatment (OMT)
Trial: 23739758
Drug: Ultrasound therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound therapy (UST)
Trial: 10778966
Drug: Preoperative irradiation
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative irradiation therapy (five doses of 5 Gy each)
Trial: 8730606
Drug: 320 ml
RxNorm normalized name: PYRITHIONE ZINC 6.4 g in 320 mL TOPICAL SHAMPOO [HAIRJOY MSM HAIR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 320 ml of red wine (providing 30 g/day of alcohol)
Trial: 8730606
Drug: 30 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g/day of alcohol diluted in 320 ml of clear fruit juice